Endonovo Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Endonovo Therapeutics generated cash of $121,870, which is more than the previous year. Cash used in financing activities reached the amount of -$120,130 last year. Net change in cash is therefore $1,740.
Cash Flow
| 2014 | -909.29K | 0 | 907.02K |
|---|---|---|---|
| 2015 | -1.01M | -3.82K | 1.06M |
| 2016 | -2.46M | 0 | 2.47M |
| 2017 | -2.98M | -3M | 6.02M |
| 2018 | -2.87M | -8.96K | 3.17M |
| 2019 | -2.54M | -2.59K | 2.18M |
| 2020 | -741.59K | 0 | 736.11K |
| 2021 | -986.58K | 0 | 1.05M |
| 2022 | -678.83K | 0 | 593K |
| 2023 | 121.87K | 0 | -120.13K |
ENDV Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 98 | 85.93K | 13.42K | 18.89K | 379.15K | 90.17K | 55.53K | 41.47K | 988 | 3.25K |
Operating activities | ||||||||||
Net income | 6.92M | -18.47M | -3.10M | -395.58K | -17.31M | -6.43M | -10.81M | -5.31M | -5.07M | -959.49K |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 646.91K | 646.91K | 648.49K | 651.24K | 650.31K | 650.21K | 14.76K | 15.83K | 14.77K | 15.73K |
Stock-based compensation expense | 686.74K | 45K | 95.25K | 456.51K | 194.65K | 0 | 1.41M | 0 | 728.75K | 0 |
| Deferred income tax benefit | 686.74K | 45K | 95.25K | 456.51K | 194.65K | 0 | 1.41M | 0 | 728.75K | 0 |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 0 | 0 | -2 | 21.8K | -19.39K | -3.34K | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 757.84K | 819.39K | 1.00M | 644.88K | 0 | 0 | 0 | 0 |
Accounts payable | -478.50K | 269.39K | -42.47K | 94.20K | 442.08K | 63.23K | 4.72M | 4.73M | 900.57K | 0 |
Cash generated by operating activities | 121.87K | -678.83K | -986.58K | -741.59K | -2.54M | -2.87M | -2.98M | -2.46M | -1.01M | -909.29K |
Investing activities | ||||||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | 0 | 0 | 0 | 0 | -2.59K | -8.96K | -3M | 0 | -3.82K | 0 |
Acquisitions Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | 0 | 0 | 0 | 0 | -2.59K | -8.96K | -3M | 0 | -3.82K | 0 |
Financing activities | ||||||||||
Common Stock Issued | 10.72K | 142K | 126K | 150K | 168.34K | 787.5K | 1.29M | 1.23M | 139.09K | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | -121.05K | 465K | -933.1K | -608.11K | 1.86M | -559.72K | 4.01M | -253.53K | 936.52K | -28.47K |
Cash used in financing activities | -120.13K | 593K | 1.05M | 736.11K | 2.18M | 3.17M | 6.02M | 2.47M | 1.06M | 907.02K |
Net Change In Cash | 1.74K | -85.83K | 72.51K | -5.47K | -360.25K | 288.97K | 34.64K | 14.06K | 40.48K | -2.26K |
Cash at end of period | 1.83K | 98 | 85.93K | 13.42K | 18.89K | 379.15K | 90.17K | 55.53K | 41.47K | 988 |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |